Application of interim PET-CT in first-line treatment decision-making for lymphoma  

作　　者：Linlin HUANG Yi ZHAO Jingsong HE 

机构地区：[1]Bone Marrow Transplantation Center,Department of Hematology,the First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310006,China

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2023年第10期905-921,共17页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：supported by the National Natural Science Foundation of China(No.82270206);the Zhejiang Provincial Natural Science Foundation of China(No.LZ22H160009).

摘　　要：Recent advances in lymphoma treatment have significantly improved the survival of patients;however,the current approaches also have varying side effects.To overcome these,it is critical to implement individualized treatment according to the patient’s condition.Therefore,the early identification of high-risk groups and targeted treatment are important strategies for prolonging the survival time and improving the quality of life of patients.Interim positron emission tomography-computed tomography(PET-CT)has a high prognostic value,which can reflect chemosensitivity and identify patients for whom treatment may fail under this regimen.To date,many prospective clinical studies on interim PET(iPET)-adapted therapy have been conducted.In this review,we focus on the treatment strategies entailed in these studies,as well as the means and timing of iPET assessment,with the aim of exploring the efficacy and existing issues regarding iPET-adapted treatment.It is expected that the improved use of PET-CT examination can facilitate treatment decision-making to identify precise treatment options.

关 键 词：Positron emission tomography-computed tomography(PET-CT) LYMPHOMA Interim PET(iPET)-adapted therapy 

分 类 号：R733.1[医药卫生—肿瘤] R730.44[医药卫生—临床医学]